Common pitfalls in preclinical cancer target validation.

Common pitfalls in preclinical cancer target validation.

Item
http://www.wikidata.org/entity/Q38775271
Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.MELK is not necessary for the proliferation of basal-like breast cancer cells.Enhancing the Promise of Drug Repositioning through Genetics.Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.Evolutionary and genetic features of drug targets.Cancer vaccine: learning lessons from immune checkpoint inhibitors.ICE1 promotes the link between splicing and nonsense-mediated mRNA decay.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment.Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.A modified gene trap approach for improved high-throughput cancer drug discovery.New Approaches to Difficult Drug Targets: The Phosphatase StoryLarge-scale investigation of the reasons why potentially important genes are ignoredMouse models in the era of large human tumour sequencing studies
P2860

Common pitfalls in preclinical cancer target validation.

Item
http://www.wikidata.org/entity/Q38775271
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Common pitfalls in preclinical cancer target validation.
@en
type
label
Common pitfalls in preclinical cancer target validation.
@en
prefLabel
Common pitfalls in preclinical cancer target validation.
@en
P1433
P1476
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P6179
P698
P356
P1433
P1476
Common pitfalls in preclinical cancer target validation.
@en
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P6179
P698